ImmuPharma PLC (LON:IMM) – BUY*: Lupuzor update
Market Cap: £61m; Current Price: 49p; Target Price: 171p
Update on Lupuzor Phase 3 trial
ImmuPharma PLC announced further details of patient participation in its flagship Phase 3 clinical trial of Lupuzor™, a potential treatment for Lupus, the auto-immune disease.
293 patients initially screened illustrating the demand from physicians for a new safe and effective treatment for Lupus.
Of these, the required 200 patients have been successfully recruited and randomised (dosed).
7 Countries and 28 sites are participating in the study.
By the end of this month, over 80% of patients will have been treated for at least 3 months.
To date no drug related 'Serious Adverse Events' have been reported.
NORTHLAND CAPITAL PARTNERS VIEW: Today’s announcement provides further details on ImmuPharma’s flagship Phase 3 clinical trial. With enrolment and dosing now complete, we have better visibility of the trial’s timetable. Given that the last patient dosed needs to be monitored for 12 months, we now expect the trial to read out top line results in Q1-18, a couple of months later than we originally expected—but now with a high degree of certainty. Importantly, no drug related 'Serious Adverse Events' have been reported to date, indicating that the drug remains safe. We reiterate that should Lupuzor be approved, we estimate it could achieve multi-billion dollar annual sales. Consequently, we calculate that ImmuPharma is grossly undervalued.
Sunrise Resources (LON:SRES) – CORP: Pozz Project update
Market Cap: £1.8m; Current Price: 0.16p
Concept study to be completed in Q117
Sunrise Resources has commissioned a Concept Study for the development of the CS natural pozzolan project, located in Nevada. It is expected to be completed by Q117.
Magmatics Inc., a consulting firm with expertise in natural pozzolans, has been retained to assist in the project development. A site visit has been conducted and additional test work samples collected.
NORTHLAND CAPITAL PARTNERS VIEW: Sunrise Resources continues to advance the CS natural pozzolan project with a concept study that will establish parameters and a timeline for commercial production. Natural pozzolans are considered a "greenhouse gas friendly" alternative to Portland cement.